Moleculin Collaborates with UTMB to Evaluate WP1122 for Multiple Viruses Including Coronavirus
Shots:
- Moleculin will provide its lead candidate- WP1122- and related inhibitors along with technical support while UTMB will investigate candidates against multiple viruses including COVID-19- in connection with UTMB’s CBEID
- UTMB’s CBEID collaborates with the Galveston National Laboratory- which is funded by NIAID the US Department of Defense- the US Centers for Disease Control & Prevention and other federal agencies along with academic partners- private foundations- and the biopharmaceutical industry
- WP1122 is a prodrug of 2-DG (2-deoxy-D-glucose) that overcome 2-DG's lack of drug-like properties and demonstrated increment in the tissue/organ concentration in its preclinical study
Click here to read full press release/ article | Ref: Moleculin | Image: Moleculin
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com